Diabetes mellitus tipo 2: Consideraciones sobre riesgo cardiovascular y rehabilitación cardiovascular. Primera parte

Lázara M. Pérez Yánez; Alain López Gutiérrez; Suilbert Rodríguez Blanco

Autores/as

Lázara M. Pérez Yánez Hospital Hermanos Ameijeiras https://orcid.org/0000-0002-7972-8752
Alain López Gutiérrez Servicio de Cardiología, Hospital Clínico-Quirúrgico Hermanos Ameijeiras. La Habana, Cuba.
Suilbert Rodríguez Blanco Servicio de Cardiología, Hospital Clínico-Quirúrgico Hermanos Ameijeiras. La Habana, Cuba. https://orcid.org/0000-0003-2280-6411

Resumen

La diabetes mellitus tipo 2 constituye una de las enfermedades crónicas con mayor prevalencia a nivel mundial y se asocia a múltiples factores de riesgo cardiovascular y a un incremento del riesgo de mortalidad por enfermedad cardiovascular. Se revisaron 58 referencias bibliográficas con el objetivo de describir elementos importantes para la estratificación del riesgo cardiovascular y en el tratamiento de algunos factores de riesgo en los pacientes con esta enfermedad.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Lázara M. Pérez Yánez, Hospital Hermanos Ameijeiras

Presidenta de la Sección Nacional de Prevención y Rehabilitación Cardiovascular de la Sociedad Cubana de Cardiología.

Jefa de la Sección de Cardiología Diagnóstica del Hospital Hermanos Ameijeiras.

Especialista de Segundo Grado en Cardiología.

Máster en Urgencias Médicas.

Profesora e Investigadora Auxiliar.

Doctora en Ciencias Médicas.

Alain López Gutiérrez, Servicio de Cardiología, Hospital Clínico-Quirúrgico Hermanos Ameijeiras. La Habana, Cuba.

Especialista de Primer Grado en Cardiología. Investigador agregado.

Suilbert Rodríguez Blanco, Servicio de Cardiología, Hospital Clínico-Quirúrgico Hermanos Ameijeiras. La Habana, Cuba.

Especialista de Primer Grado en Cardiología. Profesor Instructor.

Citas

1. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care. 2014;37(Supl 1):S14-80. DOI: https://doi.org/10.2337/dc14-s014

2. American Diabetes Association. Standards of medical care in diabetes 2015 abridged for primary care providers. Clin Diabetes. 2015;33(2):97-111. DOI: https://doi.org/10.2337/diaclin.33.2.97

3. International Diabetes Federation. IDF Diabetes Atlas: Eighth Edition 2017 [Internet]. Bruselas: International Diabetes Federation; 2017 [citado 21 Ago 2020]. Disponible en: https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf

4. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002;324(7343):939-42. DOI: https://doi.org/10.1136/bmj.324.7343.939

5. Lee C, Joseph L, Colosimo A, Dasgupta K. Mortality in diabetes compared with previous cardiovascular disease: a gender-specific meta-analysis. Diabetes Metab. 2012;38(5):420-7. DOI: https://doi.org/10.1016/j.diabet.2012.04.002

6. Stam-Slob MC, van der Graaf Y, de Borst GJ, Cramer MJ, Kappelle LJ, Westerink J, et al. Effect of Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With Symptomatic Vascular Disease at Different Locations. Diabetes Care. 2015;38(8):1528-35. DOI: https://doi.org/10.2337/dc14-2900

7. Standards of medical care in diabetes 2015: summary of revisions. Diabetes Care. 2015;38(Supl 1):54. DOI: https://doi.org/10.2337/dc15-s003

8. American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Supl 1):S86-104. DOI: https://doi.org/10.2337/dc18-s009

9. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Supl 2):S49-73. DOI: https://doi.org/10.1161/01.cir.0000437741.48606.98

10. Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, et al. Predicting macro and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care. 2013;36(5):1193-9. DOI: https://doi.org/10.2337/dc12-0958

11. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008;31(10):2006-12. DOI: https://doi.org/10.2337/dc08-0659

12. Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T, et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med. 2001;7(7):840-6. DOI: https://doi.org/10.1038/89969

13. Standards of Medical Care in Diabetes-2017: Summary of Revisions. Diabetes Care. 2017;40(Supl 1):S4-5. DOI: https://doi.org/10.2337/dc17-s003

14. Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart. 2012;98(9):691-8. DOI: https://doi.org/10.1136/heartjnl-2011-301247

15. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Rev Esp Cardiol. 2016;69(10):939.e1-87. DOI: https:/dx.doi.org/10.1016/j.recesp.2016.09.004

16. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376-414. DOI: https://doi.org/10.1016/j.jacc.2019.03.009

17. De Cosmo S, Copetti M, Lamacchia O, Fontana A, Massa M, Morini E, et al. Development and validation of a predicting model of all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2013;36(9):2830-5. DOI: https://doi.org/10.2337/dc12-1906

18. Piniés JA, González-Carril F, Arteagoitia JM, Irigoien I, Altzibar JM, Rodriguez-Murua JL, et al. Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study risk engine (BASCORE). Diabetologia. 2014;57(11):2324-33. DOI: https://doi.org/10.1007/s00125-014-3370-1

19. Piniés JA, Gonzalez-Carril F, Arteagoitia JM. Escalas de cálculo del riesgo cardiovascular para pacientes con diabetes. ¿Qué son y de qué nos sirven? Av Diabetol. 2015;31(3):102-12. DOI: http://dx.doi.org/10.1016/j.avdiab.2015.02.001

20. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(Supl 2):II1-II67. DOI: https://doi.org/10.1136/heartjnl-2014-305693

21. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015;3(5):339-55. DOI: https://doi.org/10.1016/s2213-8587(15)00081-9

22. Aboyans V, Ricco JB, Bartelink ML, Björck M, Brodmann M, Cohnert T, et al. Guía ESC 2017 sobre el diagnóstico y tratamiento de la enfermedad arterial periférica, desarrollada en colaboración con la European Society for Vascular Surgery (ESVS). Rev Esp Cardiol. 2018;71(2):111.e1-69. DOI: https://doi.org/10.1016/j.recesp.2017.12.015

23. Association American Diabetes. Updates to the Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(9):2045-7. DOI: https://doi.org/10.2337/dc18-su09

24. Jiménez-Corona A, Aguilar-Salinas C.A, Rojas-Martínez R, Hernández-Ávila M. Diabetes mellitus tipo 2 y frecuencia de acciones para su prevención y control. Salud Publica Mex. 2013;55(Supl 2):S137-43. DOI: https://doi.org/10.21149/spm.v55s2.5109

25. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(8):543-51. DOI: https://doi.org/10.7326/0003-4819-159-8-201310150-00007

26. Thomas RJ, Balady G, Banka G, Beckie TM, Chiu J, Gokak S, et al. 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2018;71(16):1814-37. DOI: https://doi.org/10.1016/j.jacc.2018.01.004

27. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. Guía de práctica Clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Rev Esp Cardiol. 2014;67(2):136.e1-56. DOI: http://dx.doi.org/10.1016/j.recesp.2013.10.015

28. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. Guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial. Rev Esp Cardiol. 2019;72(2):160.e1-78. DOI: https://doi.org/10.1016/j.recesp.2018.11.022

29. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-85. DOI: https://doi.org/10.1056/nejmoa1001286

30. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603-15. DOI: https://doi.org/10.1001/jama.2014.18574

31. Carey RM, Whelton PK. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018;168(5):351-8. DOI: https://doi.org/10.7326/m17-3203

32. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. DOI: https://doi.org/10.1056/nejmoa1603827

33. Moura CS, Rosenberg ZB, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L. Treatment discontinuation and clinical events in type 2 diabetes patients treated with dipeptidyl peptidase-4 inhibitors or NPH insulin as third-line therapy. J Diabetes Res [Internet]. 2018 [citado 5 Sep 2020];2018:4817178. Disponible en: https://doi.org/10.1155/2018/4817178

34. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. DOI: https://doi.org/10.1056/nejmoa1611925

35. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. DOI: https://doi.org/10.1056/nejmoa1504720

36. Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2018;39(5):363-70. DOI: https://doi.org/10.1093/eurheartj/ehx511

37. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. DOI: https://doi.org/10.1016/j.jacc.2013.11.002

38. Huo R, Du T, Xu Y, Xu W, Chen X, Sun K, et al. Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis. Eur J Clin Nutr. 2015;69(11):1200-8. DOI: https://doi.org/10.1038/ejcn.2014.243

39. Way KL, Hackett DA, Baker MK, Johnson NA. The Effect of Regular Exercise on Insulin Sensitivity in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Metab J. 2016;40(4):253-71. DOI: https://doi.org/10.4093/dmj.2016.40.4.253

40. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021-31. DOI: https://doi.org/10.1056/nejmoa1600176

41. Grundy SM, Stone NJ. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. Ann Intern Med. 2019;170(11):779-83. DOI: https://doi.org/10.7326/m19-0365

42. Karlson BW, Wiklund O, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):212-7. DOI: https://doi.org/10.1093/ehjcvp/pvw006

43. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72(18):2365-73. DOI: https://doi.org/10.2165/11638240-000000000-00000

44. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. DOI: https://doi.org/10.1056/nejmoa1410489

45. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study. Eur Heart J. 2015;36(36):2446-53. DOI: https://doi.org/10.1093/eurheartj/ehv251

46. Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, et al. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors. Circ Cardiovasc Qual Outcomes [Internet]. 2017 [citado 16 Sep 2020];10(1):e003153. Disponible en: https://doi.org/10.1161/circoutcomes.116.003153

47. Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, et al. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. J Am Coll Cardiol. 2017;69(5):471-82. DOI: https://doi.org/10.1016/j.jacc.2016.11.037

48. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. DOI: https://doi.org/10.1056/nejmoa1615664

49. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. DOI: https://doi.org/10.1001/jama.285.19.2486

50. Nsiah K, Shang VO, Boateng KA, Mensah FO. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res. 2015;5(2):133-8. DOI: https://doi.org/10.4103/2229-516x.157170

51. Riddle MC, Bakris G, Boulton AJ, Blonde L, D'Alessio D, Greene EL, et al. Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care. 2018;41(7):1327-9. DOI: https://doi.org/10.2337/dci18-0035

52. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315(22):2424-34. DOI: https://doi.org/10.1001/jama.2016.7602

53. Cai X, Yang W, Gao X, Zhou L, Han X, Ji L. Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis. PLoS One [Internet]. 2016 [citado 21 Sep 2020];11(12):e0166625. Disponible en: https://doi.org/10.1371/journal.pone.0166625

54. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861-77. DOI: https://doi.org/10.2337/dc16-0236

55. Wycherley TP, Clifton PM, Noakes M, Brinkworth GD. Weight loss on a structured hypocaloric diet with or without exercise improves emotional distress and quality of life in overweight and obese patients with type 2 diabetes. J Diabetes Investig. 2014;5(1):94-8. DOI: https://doi.org/10.1111/jdi.12120

56. Drugs. Phentermine FDA prescribing information, side effects and uses. Drugs [Internet].2020 [citado 22 Sep 2020]. Disponible en: https://www.drugs.com/pro/phentermine

57. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. DOI: https://doi.org/10.1056/nejmoa1411892

58. Wong RH, Scholey A, Howe PR. Assessing premorbid cognitive ability in adults with type 2 diabetes mellitus a review with implications for future intervention studies. Curr Diab Rep [Internet]. 2014 [citado 22 Sep 2020];14(11):547. Disponible en: https://doi.org/10.1007/s11892-014-0547-4